Ted W. Love - 01 Sep 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Signature
/s/ Miguel Carrillo, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Sep 2021
Net transactions value
-$139,788
Form type
4
Filing time
03 Sep 2021, 20:00:36 UTC
Previous filing
24 Sep 2021
Next filing
03 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +9,444 +1.2% 798,857 01 Sep 2021 Direct F1
transaction GBT Common Stock Tax liability $139,788 -4,683 -0.59% $29.85 794,174 01 Sep 2021 Direct F2
holding GBT Common Stock 102,000 01 Sep 2021 By Trust 1
holding GBT Common Stock 102,000 01 Sep 2021 By Trust 2
holding GBT Common Stock 102,000 01 Sep 2021 By Trust 3
holding GBT Common Stock 2,500 01 Sep 2021 By Daughter
holding GBT Common Stock 2,500 01 Sep 2021 By Daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -9,444 -12% $0.000000 66,112 01 Sep 2021 Common Stock 9,444 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,444 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.